Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

07 oct. 2025 15h39 HE | Source: MetasTx LLC

NJ-Founded MetasTx Fast-Tracks Precision Approach to Stop Prostate Cancer Spread; NCI-Backed Diagnostic in Proof-of-Concept, Next-Gen KIT Inhibitor Advancing Toward First-in-Human

NJ-founded MetasTx is advancing an NCI-backed diagnostic and next-gen KIT inhibitor for high-risk prostate cancer, aiming for 2026 validation.
25 juin 2025 07h08 HE | Source: MetasTx LLC

MetasTx Secures NCI Grant to Enable the Advancement of Dual-Track Strategy Against Metastatic Prostate Cancer

MetasTx has been awarded a NCI SBIR grant for its integrated diagnostic and therapeutic platform aimed at predicting and preventing prostate cancer.
17 oct. 2017 07h58 HE | Source: The Jackson Labratory

The Jackson Laboratory and Seven Bridges Collaborate to Build Centralized Data Platform to Advance Cancer Research

FARMINGTON, Conn., and BOSTON, Mass., Oct. 17, 2017 (GLOBE NEWSWIRE) -- The Jackson Laboratory (JAX), a nonprofit biomedical research institution, and Seven Bridges, the leading biomedical data...